Since the MYC mRNA is known to be bound and stabilized by IGF2BP1 in a m6A-dependent manner, the authors speculated that gemcitabine might interfere with the WTAP/MYC/IGF2BP1 axis to inhibit pancreatic cancer progression [152,153]. The gene discussed is MYC; the disease is pancreatic neoplasm.